| Name | Title | Contact Details |
|---|
Jnana was founded by leading academic scientists, drug developers and investors to develop medicines that transform the lives of patients by targeting the cell`s metabolic gates.
At Molecular Devices, we enable our customers to unravel the complexity of biological systems. Our innovative analytical solutions for cell and protein biology enable our customers to see more, do more, and know more, and to answer life`s most important questions. We are one of the world`s leading providers of high-performance bioanalytical measurement solutions for life science research, pharmaceutical and biotherapeutic development. With over 130,000 placements in laboratories around the world, our instruments have catalyzed brilliant scientific research described in over 25,000 peer reviewed publications. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products empower scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Our headquarters are in Silicon Valley, the hub of technology and innovation, with offices around the globe employing close to 1,000 highly skilled and passionate associates.
HomeDNA, Inc. is a Keller, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
NMD Pharma A/S is a clinical-stage biotech company developing a first-in-class platform of small molecule therapies selectively targeting the skeletal muscle chloride ion channel (ClC-1) for the treatment of severe neuromuscular disorders. The Company was incorporated as a spin-off from Aarhus University, Denmark in 2015 and was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity. NMD Pharma has built a world-leading muscle electrophysiology platform leveraging the in-depth know-how of muscle physiology and muscular disorders, small molecule modulators, enabling technologies and tools as well as in vivo pharmacology models for discovering and developing proprietary modulators of neuromuscular function. NMD Pharma received initial seed financing in 2016 and has since raised ~€155 million from investors including Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, Roche Venture Fund, and Jeito Capital.
Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in the USA, Belgium, Russia, UK, Taiwan, and China sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research. Insilico Medicine pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson`s Disease, Alzheimer`s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief.